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Applications of Lipidic and 
Polymeric Nanoparticles for 
siRNA Delivery
Behiye Şenel and Gülay Büyükköroğlu
Abstract
The antisense technology that emerged with the discovery of RNA interference 
nearly 20 years ago has gained a significant place in gene therapy. siRNA, one of two 
important components of RNA interference, efficiently downregulates gene expres-
sion in human cells, so it has the potential to eradicate disease. siRNA delivery 
systems, which can be applied both systemically and locally in different diseases, 
have gained significant importance. Naked small RNAs can be delivered directly to 
cells, but because of their instability, exposure to enzyme degradation, and difficul-
ties in reaching/entering the target cell or tissue in blood stream, these initiatives 
are failing. For this reason, the method of delivery or encapsulation of siRNA is 
usually required. Various nanoparticles, nanocapsules, emulsions, micelle systems, 
metal ion nanoparticles, and nanoconjugates have been used for siRNA delivery. 
In these transport systems, lipidic and polymeric systems are very attractive due to 
their advantages such as being biodegradable and biocompatible, safety, being able 
to electrostatically bind to RNA, long-term stability, well-illuminated structure and 
features, simple and easy production, etc. Issues such as particle size, zeta potential, 
and stability of siRNA-loaded system should be taken into consideration in the 
development of siRNA delivery systems.
Keywords: lipidic nanoparticles, polymeric nanoparticles, nanocarrier, transfection, 
barriers, siRNA delivery
1. Introduction
Noncoding RNAs have many functions such as gene silencing, DNA imprinting, 
and demethylation. An increased number of noncoding RNAs have been discovered 
in gene regulation and RNA processing. Of these, small interfering ribonucleic 
acid (siRNA) and microRNAs (miRNAs) that can interfere with the translation 
of the target mRNA transcript are small ncRNAs that are the cleavage products 
of the dsRNA. MicroRNAs are a class of endogenous RNA that results in mRNA 
translation inhibition or degradation, which regulates cell differentiation, prolifera-
tion, and survival, while synthetic siRNA can initiate the silencing of target genes 
without interrupting natural mRNA pathways.
siRNA is a promising therapeutic solution preventing gene overexpression in 
various pathological conditions such as infectious or ocular disease, cancer, and 
genetic or metabolic disorders. These therapeutic methods are currently being a 
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phenomenon in cancer therapy because siRNA is used to suppress oncogenes and 
to remove mutations and to illuminate key molecules in the cellular pathways of 
cancer [1, 2].
It is also effective in personalized gene therapy for several diseases, due to its 
specificity, compatibility, and targeting ability. Following this strategic discovery, 
many synthetic siRNAs are designed with the desired sequences to explicitly inhibit 
any target gene expression [3, 4]. However, naked siRNA is unstable in the blood-
stream and cannot effectively pass the cell membranes as well as being immuno-
genic [5].
There is a need for delivery systems in order to overcome the obstacles and to 
increase their potentials in the process of transporting siRNAs to the desired desti-
nation with minimal adverse effects and safe transportation to target areas. These 
carriers are usually provided with viral (retrovirus, lentivirus, adenovirus, adeno-
associated virus (AAV), cough viruses, human foamy viruses, and baculovirus) and 
non-viral vectors. Viral vectors are effective tools for transfection vectors which are 
efficient delivery systems that utilize genetically modified viruses, offering advan-
tages such as continuous gene silencing and the ease of expression of a large number 
of RNA interference (RNAi) molecules from a transcript [6, 7].
However, safety concerns such as oncogenicity, immunogenicity, viral genome 
insertion into host chromosomes, and expensive production limit the widespread 
use of viral vectors [8].
Until now, only one virus-mediated transport system has been authorized for 
marketing. Glybera® (alipogene tiparvovec using an adeno-associated virus as vec-
tor) was the first drug approved by the European Commission in late 2012 to treat 
lipoprotein lipase deficiency (LPLD). However, in early 2018, the most expensive 
drug in the world has been withdrawn from the market for financial reasons [9]. 
Therefore, it is important to design non-viral transport vectors for the in vivo 
delivery of siRNAs.
These delivery systems are mostly intended to make the siRNA more efficient 
for interaction with angiogenesis, metastasis, chemoresistance of tumors, and 
proliferation of cancer cells. Although these systems show encouraging results 
for possible therapeutic success, many obstacles still exist to implement them in 
humans, practically.
Delivery systems should not be immunogenic and should not cause undesirable 
side effects. In normal cells, siRNAs should avoid off-target silencing of genes [10].
The carrier systems should not be defined as foreign particles by the immune 
system elements, i.e., interferons and cytokines, and should not be eliminated 
before they reach the target. These difficulties have been overcome by the precise 
design of the siRNA to the target or by chemical modification of the relevant siRNA 
molecule.
For this reason, the use of lipidic/polymeric nanoparticles is the most common 
choice to overcome the above difficulties. These developed nanoparticles can pro-
tect the siRNA from plasmatic nucleases and unwanted immune responses, thereby 
facilitating endocytosis, designed to resist renal clearance; providing low cytotoxic-
ity, stable serum stability, and high structural and functional reliability; delivering 
the unstable naked siRNA to targeted tumor sites; and reducing interactions with 
nontarget cells [7].
They can also be used for on-target delivery by adding target-specific ligands 
to their surface. The most preferred among these transport systems are lipid-based 
and polymer-based systems. Several technologies and nanoparticle modifications 
developed in recent years and new nanoparticle raw materials have accelerated 
the development of siRNA-loaded nanoparticles with the desired structural and 
functional properties.
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DRUG name Disease or condition Target Delivery vector Phase Trial number Company Recruitment 
status
CALAA-01 Solid tumors RRM2 CD/polymer 1 NCT00689065 Calando Pharmaceuticals Terminated 
2008–2013
ALN-VSP02 Solid tumors KSP, VEGF LNP 1 NCT00882180 Alnylam Pharmaceuticals Completed 
2009–2011
Atu027 Advanced solid tumors PKN3 LNP 1 NCT00938574 Silence Therapeutics 
GmbH
Completed 
2009–2013
PRO-040201 Hypercholesterolemia ApoB SNALP 1 NCT00927459 Arbutus Biopharma 
Corporation
Terminated 
2009–2010
TKM-080301 Primary or secondary liver cancer PLK1 LNP 1 NCT01437007 National Cancer Institute 
(NCI)
Completed 
2011–2018
DCR-MYC Hepatocellular carcinoma MYC LNP 1b/2 NCT02314052 Dicerna Pharmaceuticals, 
Inc.
Terminated 
2014–2018
Solid tumors, multiple myeloma, 
lymphoma
MYC LNP 1 NCT02110563 Dicerna Pharmaceuticals, 
Inc.
Terminated 
2014–2017
siRNA-EphA2-
DOPC
Advanced solid tumors EphA2 NL 1 NCT01591356 M.D. Anderson Cancer 
Center
Recruiting 
2012–2018
ND-L02-s0201 Moderate to extensive hepatic 
fibrosis
HSP47 LNP 1 NCT01858935 Bristol-Myers Squibb Completed 
2014–2017
KSP, kinesin spindle protein; VEGF, vascular endothelial growth factor; PEI, polyethylenimine; NP, neutral liposome; CD, cyclodextrin; PKN3, protein kinase N3; PLK1, polo-like kinase-1; ApoB, MYC 
oncogene, apolipoprotein B; SNALP, stable nucleic acid lipid particle.
Table 1. 
siRNA-based clinical trials using lipidic and polymeric vectors for cancer therapy [12, 13].
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Taking advantage of these excellent properties of nanoparticles, various delivery 
systems for siRNA have recently used the clinical trial phase, and these methods are 
followed as a very effective and promising treatment for various disease.
As the latest development in this issues, the US Food and Drug Administration 
approved the Onpattro (patisiran) infusion on 10 August 2018 for the treatment of 
peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-medi-
ated amyloidosis (hATTR) in adult patients. It is also the first FDA approval of a new 
class of drugs called small interfering ribonucleic acid (siRNA) treatment. FDA antici-
pates that this is the beginning of a new and exciting generation of therapeutics [11].
Patisiran is covered in a lipid nanoparticle (LNP) that carries the drug to the 
liver, but this carrier molecule can trigger its own immune response. Therefore, 
steroid, acetaminophen, and antihistamines should be used to reduce the likelihood 
of immune reaction in patients before taking patisiran administered by intravenous 
(IV) infusion. Further research is underway to design a drug delivery system that 
can reach the target tissue without causing an immune response. Table 1 presents 
examples of clinical trials and current status of siRNAs prepared with lipidic and 
polymeric nanoparticle.
2. Physiological barriers for siRNA
The site of action of the SiRNA therapeutics is cytosol. The obstacles to siRNA 
administration vary depending on the targeted organs, disease, and routes of 
administration. In general, siRNA therapeutics are preferred as local or systemic 
injection. The local transport of siRNA has less obstruction compared to systemic 
administration. The first of the unique features of the local administration is the 
need to an easy formulation that requires easier production and application and 
secondly provides application of lower doses that limit intracellular (time-concen-
tration-dependent) immune responses [14].
Therefore, the application is limited to easily accessible tissues such as the skin, 
eye, or mucosa, but successful results have been achieved. However, for the local 
administration of siRNA, the nervous system, lung, digestive, vagina, and inner 
coronary walls were selected as target regions [15].
For example, intranasal inhalation of the siRNA against the respiratory syncytial 
virus was carried out with TransIT-TKO commercial transfection agent and was 
found significantly effective in reducing viral infection [16].
In a recent study by Wu and colleagues, they developed novel PEGylated 
lipoplex-entrapped alginate scaffold system for vaginal epithelium-targeted siRNAs 
for the treatment of HIV virus infections. They indicated in the study the potential 
of the biodegradable PLAS system for the sustained delivery of siRNA/oligonucle-
otides to vaginal epithelium [17].
The main advantage of the systemic method is rapid action and biodistribution 
but also a wide range of applications. In addition, intravenous or intraperitoneal (IP) 
injection therapy is successfully applied for many diseases in the clinic. However, it 
causes significant difficulties for siRNA in systemic transmission. The transition steps 
of the siRNA from the application site to the target action site are shown in Figure 1.
As described above, after intravenous injection (1), siRNA is distributed to 
organs through the blood stream (3) and also undergoes elimination [7].
The siRNA molecules have unwanted physicochemical properties due to their 
negative charge, large molecular weight, size, and instability. After systemic 
administration, the naked siRNA administered without vectors is rapidly degraded 
by serum endonucleases (4), excreted by the kidney (7), or taken up by the macro-
phages (APC cells) (5) of the mononuclear phagocyte system (MPS) [7, 18].
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The result is a short plasma half-life below <10 minutes, so it cannot have enough 
time to reach the target and/or perform its functions, and therefore the gene silenc-
ing is ineffective. These problems are partially addressed by chemical modifications 
of the RNA backbone and by the use of nano-sized carriers (2) [7, 60].
Nanoparticle studies showed that the nanoparticles below 6 nm were rapidly 
excreted by renal excretion and nanoparticles in the range of 150–300 nm were 
taken by the cells of the MPS in the liver and spleen. It is stated that nanoparticles 
between 30 and 150 nm can hold in the bone marrow, kidney, etc. In addition, it has 
been reported that red blood cells (RBCs) affect the transport and distribution of 
microparticles in human microvasculature (diameter <100). In fact, due to colli-
sions with RBCs, microparticles are pushed toward the artery wall where RBCs are 
virtually absent depending on the shape and size by a radial movement called the 
“waterfall effect.” This event is also called margination, and they have stated that 
the extravasation cannot occur unless vectors are exposed to margination [14].
In a study done by D’Apolito et al. [20], they found that 3-μm particles had bet-
ter marginalization than 1 μm. For this reason, it is seen that the size of the prepared 
particles could be very effective especially in in vivo experiments.
Figure 1. 
An illustration of a nanocarrier, barriers at systemic circulatory, mechanisms of uptake of siRNA from cell 
(modified from the 26th literature). In the following text, the numbers in the figure are mentioned.
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The vectors carrying siRNA enter the tissue interstitium following extravasa-
tion. After entering the tissue interstitium, siRNA is moved to the target cells across 
the interstitial space. Transport along the vessel walls can occur via diffusion, 
convection through the capillary pores, and transcytosis. The diffusion is directed 
by the concentration gradient.
One of the unique properties of tumor microvessels is leakage (6) from endothe-
lial discontinuity. The pore size of tumor microvessels ranges from 100 to 780 nm 
in diameter. In contrast, microvessels in most normal tissues have less leakage. For 
example; the tight junctions between endothelial cells are generally <2 nm, and the 
pore size in the capillary venules is <6 nm, the endothelium of the renal glomeruli 
is 40–60 nm, and the sinusoidal endothelium in the liver and spleen has large pore 
sizes of about 150 nm [19].
Leakage in tumor vessels increases siRNA/carrier extravasation, since the naked 
siRNA cannot enter the direct cell membrane due to its high molecular weight, large 
size, and negatively charged phosphate skeleton from the anionic cell membrane; 
the carrier systems are gaining importance here, again [21, 22].
There is an evidence that endocytosis (8) plays an important role, although not all 
of the entry mechanisms are well understood. The most common endocytosis used by 
nanocarriers is clathrin-mediated endocytosis through endocytic route receptor [23].
Rejman et al. [24] showed that the size and nature of the carrier vector affect 
the internalization mechanism. Nanoparticles of about 1 μm size are taken up via 
macropinocytosis, and ~120 nm size are taken up via clathrin-mediated endocyto-
sis, whereas nanoparticles ~90 nm are taken up via clathrin/caveolae-independent 
endocytosis and caveolin-mediated endocytosis [25, 26].
Besides surface properties and size of the nanoparticles, surface modifications 
of the nanoparticles are also important in siRNA transport. The most important 
of these surface modifications is the coating of nanoparticles with PEG. The 
PEGylation is performed to keep the particles in the systemic circulation longer, 
and the positive results were obtained from until today. However, in addition to 
this positive effect, it has been reported that the increased PEGylation from 1–2 to 
5% mol reduced the transfection efficiency by neutralizing the positive surface load 
required for siRNA involvement instead of increasing the transfection [27].
After reaching the target cell, the siRNA is subjected to endocytosis internal-
ization, a process involving encapsulated siRNA in endocytic vesicles fused with 
endosomes. Endocytotic vesicles are initially associated with early endosomes and 
then mature late endosomes before fusion with lysosomes in the cell. Lysosomes are 
then formed. After internalization into the cell, the siRNA should escape from the 
fragmentation in the endosomes and be released from the carrier to the cytosol in 
order to be loaded to RNA-induced silencing complex (RISC) [28].
Sardo et al. found that endosomal escape increased with another modification 
with pH-sensitive polymers. In this study, they prepared a siRNA delivery system 
based on inulin (Inu), a plenty and natural polysaccharide. Inu was functionalized 
via the conjugation with diethylenetriamine (DETA) residues to form the complex 
Inu-DETA. The results of the study showed that while homogenous diffusion 
of siRNA was performed in JHH6 cytoplasm via micropinocytosis and clathrin-
mediated endocytosis, it was found that it did not allow caveola-mediated passage 
and no siRNA activity [29].
3. Types of nanoparticulate delivery systems for siRNA delivery
This section focuses on the biodegradable non-viral lipids and polymeric 
nanosystems used in the transport of synthetic siRNA. These nanoparticles used as 
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drug delivery vehicles are carriers having a particle size of <100 nm. They are com-
posed of different biodegradable materials, such as natural or synthetic polymers, 
lipids, or metal.
The main advantages of nanoparticles used as drug carriers are achieving appro-
priate particle size, using of physiological lipids (e.g., triglycerides) and organic 
polymers (e.g., chitosan) to reduce immunogenicity, stimulating interferon-γ pro-
duction and natural killer (NK) cells, activating antitumor immunity to increase the 
effectiveness of treatment, prolongation of blood circulation in blood, and feasibility 
of variable routes of administration; they can be viewed and monitored by marking.
However, they have some disadvantages; for example, the substances used dur-
ing the formulation and the preparation methods may cause the increase of toxicity, 
sometimes failing to carry the siRNA into the cell or insufficient accumulation at 
the target site, and problems in the stability of lipidic structures like liposomes. 
These limitations, however, can be overcome by selecting the appropriate lipid or 
polymers. The advantages thus outweigh the disadvantages [30].
3.1 Lipid-based nanoparticle delivery systems
Lipid-based siRNA delivery systems include liposomes, micelles, microemul-
sions, ionizable lipids and lipid nanoparticles, and solid lipid nanoparticles.
3.1.1 Liposomes
Liposomes are spherical vesicles consisting of an aqueous core together with a 
bilayer phospholipid structure which contain natural body components (e.g., lipids, 
sterols) and are biologically compatible and biodegradable. Furthermore, lipo-
somes are popular siRNA carriers due to their relative simplicity and well-known 
pharmaceutical properties. The amphipathic nature of liposomes allows the use of a 
wide range of hydrophilic and hydrophobic drugs. The hydrophilic molecules show 
a greater affinity between the hydrophilic head groups of the phospholipid bilayer 
and the aqueous core of the liposomes, while the hydrophobic molecules intercalate 
between the fatty acyl chains of the two lipid layers [31].
As analogues of biological membranes, liposomes are fused with the plasma 
membrane and are processed by endocytosis, and the genetic material is released 
into the cytoplasm. Cationic liposomes form complexes with negatively charged 
anionic siRNAs and polycations, and the complex is called as a “lipoplex.”
However, due to their positive charge, cationic liposomes can lead to dose-
dependent cytotoxicity and inflammatory response, and the complexes can interact 
nonspecifically with negatively charged serum proteins. In order to solve these 
problems, successful tests were taken in preclinical studies of EphA2-targeted 
siRNA therapeutic using neutral lipids such as 1,2-dioleoyl-sn-glycero-3-phosphati-
dylcholine (DOPC), which proved to effectively reduce cellular toxicity [31].
Several strategies have been implemented to overcome the disadvantages of exist-
ing lipid-based systems. Modification of the lipid structure or formulation methods 
can reduce toxicity and improve transfection. The inclusion of fusogenic lipids, such 
as dioleoylphosphatidylethanolamine (DOPE), or the use of a cationic lipid consist-
ing of biodegradable ester bonds such as DOTAP may retain toxic effects at a relatively 
short or moderate level and also may increase the endosomal release of siRNA [32].
3.1.2 Solid lipid nanoparticles
SLNs having a size range of 50–1000 nm were composed from various lipids 
which are solid form at body or room temperature and can be stabilized with 
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surfactant or surfactant mixture. SLNs consist of a lipid core surrounded by a 
surfactant layer in an aqueous dispersion [33].
While being among the most effective carriers for both hydrophilic and hydro-
phobic drugs, such as liposomes, the solid, lipophilic nucleus of SLNs may have 
difficulty carrying RNA molecules that are hydrophilic and polyanionic. Therefore, 
it can be used successfully for gene delivery by addition of cationic lipids to SLNs 
which provide a positive surface potential [34].
SLNs can be easily prepared by various methods such as hot or cold homogeniza-
tion, sonication, solvent evaporation, etc., and also they have high physical stability 
and low cytotoxicity [35].
Studies with siRNAs that have been adsorbed or encapsulated into SLNs have 
also shown positive results in the literature. For example, Şenel et al. [36] pointed 
out that Bcl-2-targeted siRNAs encapsulated into SLNs prepared by sonication 
method showed an activity to be able to compete with Lipofectamine in the liposo-
mal form commercially used.
3.1.3 Nanostructured lipid carriers (NLCs)
Nanostructured lipid carriers (NLCs) are new second-generation lipid carriers 
that combine the advantages of different nanocarriers. These are solid lipid-core-
modified SLNs in which the lipid phase may comprise solid or liquid forms at 
ambient temperature [37].
Compared to SLNs, NLCs have greater loading capacity and less water in the 
dispersion, making them more stable for storage. There was no difference in 
biotoxicity. Studies have shown that NLCs can be used as a new delivery tool for the 
genetic treatment of disease. Taratula et al. prepared a multifunctional NLC system 
containing two siRNAs against cellular resistance to doxorubicin or paclitaxel 
targeting lung cancer cells. It has been found that the system successfully increases 
the antitumor activity of the anticancer drug [38, 39].
NLCs can also be modified to achieve targeting and sustained release. For 
example, by manipulating the degradation times of NLCs, it has made possible to 
obtain long-acting siRNAs. This design raised the continuous release of siRNAs to 
9 days (with a A-tailored nanostructure carrier design delivering survivin-siRNA); 
this also facilitates clinical practice of siRNA treatment [40].
3.1.4 Ionizable lipids and lipid nanoparticles (LNPs)
Recently, new lipid types have been proposed to the delivery of RNA interfer-
ence molecules. Advanced LNP siRNA systems are lipid-based particles with 
diameters <100 nm. These may consist of a mixture of an ionizable amino lipid 
(e.g., heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate, DLin-
MC3-DMA), a phosphatidylcholine, cholesterol, and a coat lipid (polyethylene 
glycol-dimiris glycerol) in a 50:10:38.5:1.5 molar ratio [41].
These lipids developed for the encapsulation of negatively charged genetic 
materials exhibit pH-dependent charge change. These lipids are positive at acidic 
pH and are neutral at physiological pH. Thus, under acidic conditions, nucleic acids 
are encapsulated in the nanoparticle and have a minimum positive charge density in 
the bloodstream. LNP siRNA systems are produced by rapidly mixing the lipids in 
ethanol with the siRNA in aqueous buffer (pH 4.0) followed by removal of ethanol 
via dialysis against PBS buffer after the pH is raised to 7.4 [42].
The genetic material carrier formulations generated by ionizable cationic 
lipids have been shown to be of significant success in in vivo activity after the 
initial administration in hepatocytes. Other tissues used for gene silencing include 
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macrophages, osteoclasts, and osteoblasts in the “hard” bone and distal tumor 
cells [43, 44].
Other siRNA administration methods have used lipid-like molecules called 
“lipidoids” for the delivery of siRNA. Lipidoid delivery systems are similar to 
ionizable cationic LNP systems due to the use of lipid-like molecules, cholesterol, 
and PEG-lipid. The most important difference of LNPs using lipidoid is that the 
lipidoid molecules have an extra positive charge because they have a large number 
of protonizable amine bound to various acyl chains. Similar to studies with cationic 
lipids, lipidoid systems developed by screening programs have been described in the 
literature [45].
Ball et al. developed a potent and nontoxic lipidoid nanoparticle (LNP) for 
intestinal epithelial cells. In the initial studies, it was reported that GAPDH siRNA-
loaded LNPs for Caco-2 cells mediated strong, dose-dependent, and resistant gene 
silencing with a single 10-nM dose for 1 week [46].
3.2 Polymer-based delivery
Polymers of natural and synthetic origin have been used for various biomedical 
applications including drug targeting, imaging, gene therapy, prostheses, tissue 
engineering, etc. Because of their reproducible properties in terms of molecular 
weight, degradation, and mechanical properties, synthetic polymers are attractive 
for therapeutic applications. The most commonly used polymers include polyethyl-
enimine (PEI), PLGA, PEG, PLL, PLA, etc. However, the synthetic polymers have 
the disadvantage biologically, such as they can turn into undesirable side effects 
or fail to achieve the desired bioactivity and biocompatibility. On the other hand, 
natural polymers are abundant and are similar to components of those found in 
biological extracellular matrices. Thus, the natural polymers have high bioactivity 
and biocompatibility. Natural polymers include polysaccharides, proteins, and 
polyesters [47].
3.2.1 Synthetic polymers
Linear or branched cationic polymers are effective transfection agents for 
genetic material. The structural and chemical properties of these polymers are well 
known. This makes them advantageous for siRNA transport. The positively charged 
polymers form “polyplexes” with negatively charged nucleic acid phosphates 
through electrostatic interactions [48].
The polymer size, the molecular weight, the degree of polymer branching, and 
the charge density, as well as the composition of the formulation medium and the 
positive and negative charges ratio between of the polymer and the oligonucle-
otides, affect the transfection efficiency and biological activity of the polyplexes.
Synthetic-based cationic polymers such as PLL, PLA, and PEI are the most 
studied polymers for in vitro and in vivo transport of siRNA. The size of the com-
plexes is one of the most important factors affecting cellular uptake. Due to their 
small size, the cationic polymers generally complex with the genetic material more 
effectively than lipids. In addition, owing to being mostly synthetic, they have some 
special feature such as customized size, branching, and composition, and these 
features can be easily changed [49].
These polymers used for siRNA delivery is well-studied, biodegradable, biocom-
patible, and capable of exhibiting nucleic acid sustained release in pharmaceutical 
applications for decades.
PEI was used to create cationic charges on the surface of PLGA particles, which 
allowed the complexation of nucleic acids on the surface of the particles [50].
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In a study done by Patil and Panyam [51], siRNA encapsulation studies were 
performed in PLGA nanoparticles. These nanoparticles were prepared by the sol-
vent evaporation method. In this method, a cationic polymer, PEI, was added to the 
PLGA matrix, and ultimately it has been reported that nanoparticles can penetrate 
into the cell at twice the rate.
Furthermore, cationic polymers with high charge densities have “proton sponge” 
properties that stimulate escape from endosomes and protect genetic materials 
from degradation. For example, PEI, by pulling and sustaining a significant amount 
of protons, induces osmotic swelling and rupture of endosomes, causing the genetic 
material to be released from the nanoparticles in the cytoplasm and thus preventing 
the transport to lysosomes and degradation of genetic material [52].
In another study, the hydrogel scaffold based on polyamidoamine (PAMAM) 
dendrimer cross-linked with dextran aldehyde was prepared to improve the stability 
of the nanoparticle. These nanoparticle systems were found to be effective for gene 
silencing [53].
3.2.2 Natural polymers
Many polysaccharides in natural Polymer structure are used for siRNA. 
Polysaccharides are generally biocompatible polymers. The main advantage is the 
presence of different functional groups (i.e., carboxyl, hydroxyl, amine) which 
enable functionalization to obtain structural heterogeneity and copolymers [54].
The most commonly used polysaccharides for siRNA administration include 
chitosan, which contains both biodegradable, biocompatible, low-cost, low cytotox-
icity hydroxyl and amines. The presence of primary amino groups (pKa ≈ 6) makes 
the chitosan a polycation that promotes the association with nucleic acids and also 
the formation of polyplex [55].
In order to increase the solubility of chitosan, various modifications have been 
done and water-soluble chitololigosaccharides have been obtained. These chitololi-
gosaccharides were used for delivery of the siRNA [35, 56].
Collagen is another biologically compatible and safe natural polymer and is a 
suitable carrier for drug delivery. In a study performed by Peng et al., localized and 
sustained release of siRNA-loaded collagen formulations were prepared for use 
in vivo gastric cancer, and positive results were obtained [57].
3.3 Lipid-polymer hybrid nanoparticles
Lipid-polymer hybrid nanoparticles (LPNs) were developed to eliminate the disad-
vantages of polymeric and lipid-based nanoparticles. The precious properties of LPNs 
containing polymer cores and lipid shells carry the complementary properties of both 
materials. In a study on the administration of LPNs in cancer treatment, the lipid/rPAA-
Chol polymer hybrid nanoparticles were modified with PEG and T7 peptide; tumor has 
been shown to be largely inhibited without activating the immune system [58].
In another study, LPNs were used for the antitumoral effect in the pancreatic 
tumor model in combination with hypoxia-inducible factor 1α (HIF1alpha)-
targeted siRNA and gemitabicin. This prepared LPN complex showed an excellent 
ability to inhibit tumor metastasis in an orthotopic tumor model [59].
4. Conclusion
In recent years, siRNA has been widely used as a promising therapeutic phenom-
enon to many pathological conditions. Progress has been made in researching target 
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genes and in the development of delivery systems for siRNA. However, challenges 
remain for successful clinical application of RNAi-based therapeutics. Safety 
concerns are the main reason for the withdrawal of clinical trials of some RNAi 
therapies.
Since its discovery, siRNA therapeutics have been actively used because of their 
high specificity, easy modifications, and unlimited therapeutic targets. However, 
the instability in the bloodstream and the problems with the accumulation in 
the target region necessitated the application of these therapeutics in a transport 
system.
The lipidic and polymeric nanoparticle systems described in this chapter are one 
step ahead the systems than other nanoparticle systems and have been proven to be 
of importance in these delivery processes in recent years. New modified systems are 
being developed to ensure safe and targeted distribution of siRNA. According to the 
results obtained from studies, new formulations are expected to reach clinical trials 
very soon such as patisiran.
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